# EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)

> **NCT03287609** · PHASE3 · COMPLETED · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 308 (actual)

## Conditions studied

- Acute Coronary Syndrome

## Interventions

- **DRUG:** Evolocumab 140 mg/mL
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03287609
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-23
- **Primary completion:** 2019-05-20
- **Final completion:** 2019-08-07
- **Target enrollment:** 308 (ACTUAL)
- **Last updated:** 2019-08-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03287609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03287609, "EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03287609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*